Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel S Merseburger

Showing results (291-300 of 323) with videos related to

Pageof 33
Sort By:
Carcinogenesis|September 6, 2021
Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastasesAnne Offermann, Duan Kang, Christian Watermann, et al.
World Journal of Urology|December 1, 2021
Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitalsJulian P Struck, Maike Schnoor, Andrea Schulze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2021
HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder CancerSarrah L Hasanali, Daley S Morera, Ronny R Racine, et al.
European Urology Focus|November 10, 2020
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract CarcinomaJens Bedke, Axel S Merseburger, Yohann Loriot, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
European Urology Focus|January 26, 2021
A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption, and Metabolic SyndromeJunjie Huang, David Ka-Wai Leung, Erica On-Ting Chan, et al.
The Lancet. Oncology|October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 studyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
The Lancet. Oncology|June 16, 2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2016
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center StudyMaria Frantzi, Kim E van Kessel, Ellen C Zwarthoff, et al.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
Pageof 33

Showing results (291-300 of 323) with videos related to

Sort By:
Pageof 33
Carcinogenesis|September 6, 2021
Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastasesAnne Offermann, Duan Kang, Christian Watermann, et al.
World Journal of Urology|December 1, 2021
Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitalsJulian P Struck, Maike Schnoor, Andrea Schulze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2021
HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder CancerSarrah L Hasanali, Daley S Morera, Ronny R Racine, et al.
European Urology Focus|November 10, 2020
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract CarcinomaJens Bedke, Axel S Merseburger, Yohann Loriot, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
European Urology Focus|January 26, 2021
A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption, and Metabolic SyndromeJunjie Huang, David Ka-Wai Leung, Erica On-Ting Chan, et al.
The Lancet. Oncology|October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 studyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
The Lancet. Oncology|June 16, 2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2016
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center StudyMaria Frantzi, Kim E van Kessel, Ellen C Zwarthoff, et al.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
Pageof 33